Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Preferred Dividend Payments: 2014-2015

  • Lineage Cell Therapeutics' Preferred Dividend Payments fell 1666.04% to -$830,000 in Q4 2015 from the same period last year, while for Dec 2015 it was -$380,000, marking a year-over-year change of. This contributed to the annual value of -$415,000 for FY2015, which is 577.01% down from last year.
  • Lineage Cell Therapeutics' Preferred Dividend Payments amounted to -$830,000 in Q4 2015, which was down 328.65% from $363,000 recorded in Q3 2015.
  • Over the past 5 years, Lineage Cell Therapeutics' Preferred Dividend Payments peaked at $363,000 during Q3 2015, and registered a low of -$830,000 during Q4 2015.
  • Over the past 2 years, Lineage Cell Therapeutics' median Preferred Dividend Payments value was $43,500 (recorded in 2014), while the average stood at -$95,000.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Preferred Dividend Payments was 967.65% (2015), while the steepest drop was 1,666.04% (2015).
  • Quarterly analysis of 2 years shows Lineage Cell Therapeutics' Preferred Dividend Payments stood at $53,000 in 2014, then plummeted by 1,666.04% to -$830,000 in 2015.
  • Its last three reported values are -$830,000 in Q4 2015, $363,000 for Q3 2015, and $53,000 during Q4 2014.